Cephalosporin resistance, tolerance, and approaches to improve their activities.
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
11
07
2023
accepted:
05
11
2023
revised:
23
10
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.
Identifiants
pubmed: 38114565
doi: 10.1038/s41429-023-00687-y
pii: 10.1038/s41429-023-00687-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.
Références
Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999;74:187–95.
pubmed: 10069359
doi: 10.4065/74.2.187
Brotzu G. Research on a new antibiotic. Cagliari Inst Hyg. 1948;1:5–15.
Newton GG, Abraham EP. Cephalosporin C, a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature. 1955;175:548.
pubmed: 14370161
doi: 10.1038/175548a0
Abraham EP. Cephalosporins 1945–1986. Drugs. 1987;34:1–14.
pubmed: 3319494
doi: 10.2165/00003495-198700342-00003
Chauvette RR, et al. Chemistry of Cephalosporin Antibiotics .2. Preparation of a new class of antibiotics and relation of structure to activity. J Am Chem Soc. 1962;84:3401.
doi: 10.1021/ja00876a035
Godzeski CW, Brier G, Pavey DE. Cephalothin, a new cephalosporin with a broad antibacterial spectrum. I. In vitro studies employing the gradient plate technique. Appl Microbiol. 1963;11:122–7.
pubmed: 13963283
pmcid: 1057954
doi: 10.1128/am.11.2.122-127.1963
Griffith RS, Black HR. Cephalothin-a new antibiotic. Preliminary clinical and laboratory studies. JAMA. 1964;189:823–8.
pubmed: 14172279
doi: 10.1001/jama.1964.03070110025005
Chang TW, Weinstein L. In vitro biological activity of cephalothin. J Bacteriol. 1963;85:1022–7.
pubmed: 14043989
pmcid: 278278
doi: 10.1128/jb.85.5.1022-1027.1963
WHO model list of essential medicines - 22nd list. World Health Organization, Document: WHO/MHP/HPS/EML/2021.02 (2021).
The WHO AWaRe (Access, Watch, Reserve) antibiotic book. World Health Organization, Document: ISBN 978-92-4-006238-2 (2022).
Goldstein E. Rise in the prevalence of resistance to extended-spectrum cephalosporins in the USA, nursing homes and antibiotic prescribing in outpatient and inpatient settings. J Antimicrob Chemother. 2021;76:2745–7.
pubmed: 34297821
pmcid: 8521393
doi: 10.1093/jac/dkab251
Penalva G, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24:1900656.
Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results? Comment. Lancet Microbe. 2021;2:E648–E649.
pubmed: 35544102
pmcid: 9743357
doi: 10.1016/S2666-5247(21)00271-8
Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect Dis. 2021;21:597–8.
pubmed: 33894839
pmcid: 8175093
doi: 10.1016/S1473-3099(21)00194-8
Jia X, et al. Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia. Int J Antimicrob Agents. 2020;55:105832.
pubmed: 31669739
doi: 10.1016/j.ijantimicag.2019.10.013
Kishii K, Ito T, Watanabe S, Okuzumi K, Hiramatsu K. Recurrence of heterogeneous methicillin-resistant Staphylococcus aureus (MRSA) among the MRSA clinical isolates in a Japanese university hospital. J Antimicrob Chemother. 2008;62:324–8.
pubmed: 18467309
doi: 10.1093/jac/dkn186
Ma W, Sun J, Yang S, Zhang L. Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China. Eur J Clin Microbiol Infect Dis. 2016;35:571–8.
pubmed: 26815433
doi: 10.1007/s10096-015-2572-x
Bryson D, Hettle AG, Boraston AB, Hobbs JK. Clinical mutations that partially activate the stringent response confer multidrug tolerance in Staphylococcus aureus. Antimicrob Agents Ch. 2020;64:e02103–19.
doi: 10.1128/AAC.02103-19
Hamad MA, Austin CR, Stewart AL, Higgins M, Vazquez-Torres A, Voskuil MI. Adaptation and Antibiotic tolerance of anaerobic Burkholderia pseudomallei. Antimicrob Agents Ch. 2011;55:3313–23.
doi: 10.1128/AAC.00953-10
Hemsley CM, Luo JX, Andreae CA, Butler CS, Soyer OS, Titball RW. Bacterial drug tolerance under clinical conditions is governed by anaerobic adaptation but not anaerobic respiration. Antimicrob Agents Ch. 2014;58:5775–83.
doi: 10.1128/AAC.02793-14
Zhang SS, Liu S, Wu N, Yuan YH, Zhang WH, Zhang Y. Small non-coding RNA RyhB mediates persistence to multiple antibiotics and stresses in Uropathogenic Escherichia coli by reducing cellular metabolism. Front Microbiol. 2018;9:1–10.
Abraham EP. A glimpse of the early history of the cephalosporins. Rev Infect Dis. 1979;1:99–105.
pubmed: 400942
doi: 10.1093/clinids/1.1.99
Bo G. Giuseppe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect. 2000;6:6–9.
pubmed: 11449655
doi: 10.1111/j.1469-0691.2000.tb02032.x
Brakhage AA. Molecular regulation of beta-lactam biosynthesis in filamentous fungi. Microbiol Mol Biol Rev. 1998;62:547–85.
pubmed: 9729600
pmcid: 98925
doi: 10.1128/MMBR.62.3.547-585.1998
Hu Y, Zhu B. Study on genetic engineering of Acremonium chrysogenum, the cephalosporin C producer. Synth Syst Biotechnol. 2016;1:143–9.
pubmed: 29062938
pmcid: 5640796
doi: 10.1016/j.synbio.2016.09.002
Abraham E. Selective reminiscences of beta-lactam antibiotics: early research on penicillin and cephalosporins. Bioessays. 1990;12:601–6.
pubmed: 2080915
doi: 10.1002/bies.950121208
Abraham EP, Newton GGF, Hale CW. Purification and some properties of Cephalosporin-N, a new Penicillin. Biochem J. 1954;58:94–102.
pubmed: 13198858
pmcid: 1269848
doi: 10.1042/bj0580094
Hamilton-Miller JMT. Sir Edward Abraham’s contribution to the development of the cephalosporins: a reassessment. Int J Antimicrob Ag. 2000;15:179–84.
doi: 10.1016/S0924-8579(00)00179-5
Hamilton-Miller JMT. The cephalosporins and Sir Edward Abraham: Recollections about a great scientist and his part in the discovery of these antibiotics. J Antibiot. 2000;53:1003–7.
doi: 10.7164/antibiotics.53.1003
Hodgkin DC, Maslen EN. The x-ray analysis of the structure of cephalosporin C. Biochem J. 1961;79:393–402.
pubmed: 13714852
pmcid: 1205851
doi: 10.1042/bj0790393
Elks J. Structural formulae and nomenclature of the cephalosporin antibiotics. Drugs. 1987;34:240–6.
pubmed: 3691335
doi: 10.2165/00003495-198700342-00017
Lin XM, Kuck U. Cephalosporins as key lead generation beta-lactam antibiotics. Appl Microbiol Biot. 2022;106:8007–20.
doi: 10.1007/s00253-022-12272-8
Byford MF, Baldwin JE, Shiau CY, Schofield CJ. The mechanism of ACV Synthetase. Chem Rev. 1997;97:2631–50.
pubmed: 11851475
doi: 10.1021/cr960018l
Baldwin JE, Gagnon J, Ting HH. N-Terminal Amino-acid sequence and some properties of Isopenicillin-N Synthetase from Cephalosporium-Acremonium. Febs Lett. 1985;188:253–6.
pubmed: 3839755
doi: 10.1016/0014-5793(85)80382-3
Pang CP, et al. Purification of isopenicillin N synthetase. Biochem J. 1984;222:789–95.
pubmed: 6435606
pmcid: 1144243
doi: 10.1042/bj2220789
Randall CR, et al. X-ray-absorption studies of the ferrous active-site of Isopenicillin N-Synthase and related model complexes. Biochem-Us. 1993;32:6664–73.
doi: 10.1021/bi00077a020
Roach PL, et al. Structure of isopenicillin N synthase complexed with substrate and the mechanism of penicillin formation. Nature. 1997;387:827–30.
pubmed: 9194566
doi: 10.1038/42990
Ullan RV, Casqueiro J, Banuelos O, Fernandez FJ, Gutierrez S, Martin JF. A novel epimerization system in fungal secondary metabolism involved in the conversion of isopenicillin N into penicillin N in Acremonium chrysogenum. J Biol Chem. 2002;277:46216–25.
pubmed: 12228250
doi: 10.1074/jbc.M207482200
Brewer SJ, Farthing JE, Turner MK. The oxygenation of the 3-methyl group of 7beta-(5-D-aminoadipamido)-3-methylceph-3-em-4-carboxylic acid (desacetoxycephalosporin C) by extracts of Acremonium chrysogenum [proceedings]. Biochem Soc Trans. 1977;5:1024–6.
pubmed: 562287
doi: 10.1042/bst0051024
Dotzlaf JE, Yeh WK. Copurification and characterization of deacetoxycephalosporin C synthetase/hydroxylase from Cephalosporium acremonium. J Bacteriol. 1987;169:1611–8.
pubmed: 3558321
pmcid: 211989
doi: 10.1128/jb.169.4.1611-1618.1987
Higgens CE, Hamill RL, Sands TH, Hoehn MM, Davis NE. Letter: The occurrence of deacetoxycephalosporin C in fungi and streptomycetes. J Antibiot. 1974;27:298–300.
doi: 10.7164/antibiotics.27.298
Rabe P, Kamps J, Schofield CJ, Lohans CT. Roles of 2-oxoglutarate oxygenases and isopenicillin N synthase in beta-lactam biosynthesis. Nat Prod Rep. 2018;35:735–56.
pubmed: 29808887
pmcid: 6097109
doi: 10.1039/C8NP00002F
Samson SM, et al. Cloning and expression of the fungal expandase hydroxylase gene involved in cephalosporin biosynthesis. Bio-Technol. 1987;5:1207. +
Kupka J, Shen YQ, Wolfe S, Demain AL. Studies on the ring-cyclization and ring-expansion enzymes of beta-lactam biosynthesis in Cephalosporium acremonium. Can J Microbiol. 1983;29:488–96.
pubmed: 6688373
doi: 10.1139/m83-078
Lejon S, Ellis J, Valegard K. The last step in cephalosporin C formation revealed: crystal structures of deacetylcephalosporin C acetyltransferase from Acremonium chrysogenum in complexes with reaction intermediates. J Mol Biol. 2008;377:935–44.
pubmed: 18279889
doi: 10.1016/j.jmb.2008.01.047
Schmitt EK, Hoff B, Kuck U. Regulation of cephalosporin biosynthesis. Adv Biochem Eng Biotechnol. 2004;88:1–43.
pubmed: 15719551
Gutierrez S, Diez B, Montenegro E, Martin JF. Characterization of the Cephalosporium acremonium pcbAB gene encoding alpha-aminoadipyl-cysteinyl-valine synthetase, a large multidomain peptide synthetase: linkage to the pcbC gene as a cluster of early cephalosporin biosynthetic genes and evidence of multiple functional domains. J Bacteriol. 1991;173:2354–65.
pubmed: 1706706
pmcid: 207788
doi: 10.1128/jb.173.7.2354-2365.1991
Martin JF, Ullan RV, Casqueiro J. Novel genes involved in cephalosporin biosynthesis: the three-component isopenicillin N epimerase system. Adv Biochem Eng Biotechnol. 2004;88:91–109.
pubmed: 15719553
Gutierrez S, Velasco J, Fernandez FJ, Martin JF. The Cefg gene of Cephalosporium-Acremonium is linked to the Cefef gene and encodes a Deacetylcephalosporin-C Acetyltransferase closely related to Homoserine O-Acetyltransferase. J Bacteriol. 1992;174:3056–64.
pubmed: 1569032
pmcid: 205961
doi: 10.1128/jb.174.9.3056-3064.1992
Teijeira F, Ullan RV, Guerra SM, Garcia-Estrada C, Vaca I, Martin JF. The transporter CefM involved in translocation of biosynthetic intermediates is essential for cephalosporin production. Biochem J. 2009;418:113–24.
pubmed: 18840096
doi: 10.1042/BJ20081180
Ullan RV, Teijeira F, Guerra SM, Vaca I, Martin JF. Characterization of a novel peroxisome membrane protein essential for conversion of isopenicillin N into cephalosporin C. Biochem J. 2010;432:227–36.
pubmed: 20819073
doi: 10.1042/BJ20100827
Ullan RV, Liu G, Casqueiro J, Gutierrez S, Banuelos O, Martin JF. The cefT gene of Acremonium chrysogenum C10 encodes a putative multidrug efflux pump protein that significantly increases cephalosporin C production. Mol Genet Genom. 2002;267:673–83.
doi: 10.1007/s00438-002-0702-5
Gutierrez S, Fierro F, Casqueiro J, Martin JF. Gene organization and plasticity of the beta-lactam genes in different filamentous fungi. Anton Leeuw Int J G 1999;75:81–94.
doi: 10.1023/A:1001861025070
Liu L, Chen Z, Liu W, Ke X, Tian X, Chu J. Cephalosporin C biosynthesis and fermentation in Acremonium chrysogenum. Appl Microbiol Biotechnol. 2022;106:6413–26.
pubmed: 36114850
doi: 10.1007/s00253-022-12181-w
Skatrud PL, Queener SW. An electrophoretic molecular karyotype for an industrial strain of Cephalosporium acremonium. Gene. 1989;78:331–8.
pubmed: 2673927
doi: 10.1016/0378-1119(89)90235-7
Smith DJ, et al. Beta-Lactam antibiotic biosynthetic genes have been conserved in clusters in Prokaryotes and Eukaryotes. Embo J. 1990;9:741–7.
pubmed: 2107074
pmcid: 551730
doi: 10.1002/j.1460-2075.1990.tb08168.x
Pollegioni L, Rosini E, Molla G. Cephalosporin C acylase: dream and(/or) reality. Appl Microbiol Biotechnol. 2013;97:2341–55.
pubmed: 23417342
doi: 10.1007/s00253-013-4741-0
Bianchi D, Bortolo R, Golini P, Cesti P. Enzymatic transformation of cephalosporin C to 7-ACA by simultaneous action of immobilized d-amino acid oxidase and glutaryl-7-ACA acylase. Appl Biochem Biotech. 1998;73:257–68.
doi: 10.1007/BF02785660
Elander RP. Industrial production of beta-lactam antibiotics. Appl Microbiol Biotechnol. 2003;61:385–92.
pubmed: 12679848
doi: 10.1007/s00253-003-1274-y
Bush K, Bradford PA. beta-Lactams and beta-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016;6:a025247.
Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A focus on side chains and beta-lactam cross-reactivity. Pharmacy. 2019;7:103.
Giamarellou H. Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections. J Chemother. 1999;11:486–93.
pubmed: 10678790
doi: 10.1179/joc.1999.11.6.486
Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990;34:337–42.
pubmed: 2109581
pmcid: 171583
doi: 10.1128/AAC.34.2.337
Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MGP, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Ch. 2001;45:825–36.
doi: 10.1128/AAC.45.3.825-836.2001
Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemoth. 2010;65:713–6.
doi: 10.1093/jac/dkp503
Pfaller MA, et al. Ceftobiprole activity against gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2018;63:e01566-18.
Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49:3501–12.
pubmed: 16048970
pmcid: 1196228
doi: 10.1128/AAC.49.8.3501-3512.2005
Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010;54:1213–7.
pubmed: 20086158
pmcid: 2825979
doi: 10.1128/AAC.01104-09
Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2013;12:22.
pubmed: 23984642
pmcid: 3846448
doi: 10.1186/1476-0711-12-22
Spratt BG. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci USA. 1975;72:2999–3003.
pubmed: 1103132
pmcid: 432906
doi: 10.1073/pnas.72.8.2999
Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32:234–58.
pubmed: 18266856
doi: 10.1111/j.1574-6976.2008.00105.x
Sauvage E, Terrak M. Glycosyltransferases and Transpeptidases/Penicillin-binding proteins: valuable targets for new antibacterials. Antibiotics. 2016;5:1–27.
doi: 10.3390/antibiotics5010012
Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci USA. 1965;54:1133–41.
pubmed: 5219821
pmcid: 219812
doi: 10.1073/pnas.54.4.1133
Nikaido H. Crossing the envelope: how cephalosporins reach their targets. Clin Microbiol Infec. 2000;6:22–26.
doi: 10.1111/j.1469-0691.2000.tb02036.x
Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794:808–16.
pubmed: 19100346
doi: 10.1016/j.bbapap.2008.11.005
Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25:1340.
Balaban NQ, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17:441–8.
pubmed: 30980069
pmcid: 7136161
doi: 10.1038/s41579-019-0196-3
Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10:165.
Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–30.
pubmed: 27080241
doi: 10.1038/nrmicro.2016.34
Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther. 2014;12:1221–36.
pubmed: 25199988
pmcid: 4433168
doi: 10.1586/14787210.2014.956092
Arbeloa A, et al. Role of class A penicillin-binding proteins in PBP5-mediated beta-lactam resistance in Enterococcus faecalis. J Bacteriol. 2004;186:1221–8.
pubmed: 14973044
pmcid: 344401
doi: 10.1128/JB.186.5.1221-1228.2004
Lazzaro LM, Cassisi M, Stefani S, Campanile F. Impact of PBP4 alterations on beta-Lactam resistance and ceftobiprole non-susceptibility among Enterococcus faecalis Clinical Isolates. Front Cell Infect Mi. 2022;11:1–9.
Moon TM, et al. The structures of penicillin-binding protein 4 (PBP4) and PBP5 from Enterococci provide structural insights into beta-lactam resistance. J Biol Chem. 2018;293:18574–84.
pubmed: 30355734
pmcid: 6290140
doi: 10.1074/jbc.RA118.006052
Rice LB, et al. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother. 2004;48:3028–32.
pubmed: 15273117
pmcid: 478487
doi: 10.1128/AAC.48.8.3028-3032.2004
Vesic D, Kristich CJ. MurAA is required for intrinsic Cephalosporin resistance of Enterococcus faecalis. Antimicrob Agents Ch. 2012;56:2443–51.
doi: 10.1128/AAC.05984-11
Fergestad ME, Stamsas GA, Morales Angeles D, Salehian Z, Wasteson Y, Kjos M. Penicillin-binding protein PBP2a provides variable levels of protection toward different beta-lactams in Staphylococcus aureus RN4220. Microbiologyopen. 2020;9:e1057.
pubmed: 32419377
pmcid: 7424258
doi: 10.1002/mbo3.1057
Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54:1670–7.
pubmed: 20194704
pmcid: 2863635
doi: 10.1128/AAC.00019-10
Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: A novel cephalosporin with activity against Methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52:1156–63.
pubmed: 21467022
doi: 10.1093/cid/cir147
Tomberg J, et al. Alanine 501 mutations in Penicillin-binding Protein 2 from Neisseria gonorrhoeae: Structure, mechanism, and effects on cephalosporin resistance and biological fitness. Biochem-Us. 2017;56:1140–50.
doi: 10.1021/acs.biochem.6b01030
Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991;35:2312–7.
pubmed: 1804003
pmcid: 245377
doi: 10.1128/AAC.35.11.2312
Hedge PJ, Spratt BG. Resistance to beta-lactam antibiotics by re-modelling the active site of an E. coli penicillin-binding protein. Nature. 1985;318:478–80.
pubmed: 3906408
doi: 10.1038/318478a0
Alm RA, Johnstone MR, Lahiri SD. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother. 2015;70:1420–8.
pubmed: 25634992
doi: 10.1093/jac/dku568
Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161–82.
pubmed: 19136439
pmcid: 2620637
doi: 10.1128/CMR.00036-08
Mammeri H, Poirel L, Fortineau N, Nordmann P. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob Agents Chemother. 2006;50:2573–6.
pubmed: 16801449
pmcid: 1489779
doi: 10.1128/AAC.01633-05
Berrazeg M, et al. Mutations in beta-Lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother. 2015;59:6248–55.
pubmed: 26248364
pmcid: 4576058
doi: 10.1128/AAC.00825-15
Hidri N, et al. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC beta-lactamase of a Serratia marcescens clinical isolate. J Antimicrob Chemoth. 2005;55:496–9.
doi: 10.1093/jac/dki025
Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell. 1997;88:823–32.
pubmed: 9118225
doi: 10.1016/S0092-8674(00)81928-5
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969–76.
pubmed: 19995920
doi: 10.1128/AAC.01009-09
Castanheira M, Simner PJ, Bradford PA. Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021;3:dlab092.
pubmed: 34286272
pmcid: 8284625
doi: 10.1093/jacamr/dlab092
Bahr G, Gonzalez LJ, Vila AJ. Metallo-beta-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design. Chem Rev. 2021;121:7957–8094.
pubmed: 34129337
pmcid: 9062786
doi: 10.1021/acs.chemrev.1c00138
Mojica MF, Rossi MA, Vila AJ, Bonomo RA. The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022;22:e28–e34.
pubmed: 34246322
doi: 10.1016/S1473-3099(20)30868-9
Charrel RN, Pages JM, De Micco P, Mallea M. Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Chemother. 1996;40:2854–8.
pubmed: 9124854
pmcid: 163635
doi: 10.1128/AAC.40.12.2854
Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol. 2008;6:893–903.
pubmed: 18997824
doi: 10.1038/nrmicro1994
Choi U, Lee CR. Distinct roles of outer membrane porins in antibiotic resistance and membrane integrity in Escherichia coli. Front Microbiol. 2019;10:953.
pubmed: 31114568
pmcid: 6503746
doi: 10.3389/fmicb.2019.00953
Harder KJ, Nikaido H, Matsuhashi M. Mutants of Escherichia-Coli that are resistant to certain Beta-Lactam compounds lack the Ompf Porin. Antimicrob Agents Ch. 1981;20:549–52.
doi: 10.1128/AAC.20.4.549
Stephan J, Mailaender C, Etienne G, Daffe M, Niederweis M. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004;48:4163–70.
pubmed: 15504836
pmcid: 525411
doi: 10.1128/AAC.48.11.4163-4170.2004
Domenech-Sanchez A, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003;47:3332–5.
pubmed: 14506051
pmcid: 201126
doi: 10.1128/AAC.47.10.3332-3335.2003
Bredin J, et al. Alteration of pore properties of Escherichia coli OmpF induced by mutation of key residues in anti-loop 3 region. Biochem J. 2002;363:521–8.
pubmed: 11964152
pmcid: 1222504
doi: 10.1042/bj3630521
De E, et al. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol Microbiol. 2001;41:189–98.
pubmed: 11454211
doi: 10.1046/j.1365-2958.2001.02501.x
Simonet V, Mallea M, Pages JM. Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel. Antimicrob Agents Ch. 2000;44:311–5.
doi: 10.1128/AAC.44.2.311-315.2000
Pagel M, Simonet V, Li J, Lallemand M, Lauman B, Delcour AH. Phenotypic characterization of pore mutants of the Vibrio cholerae porin OmpU. J Bacteriol. 2007;189:8593–8600.
pubmed: 17905973
pmcid: 2168952
doi: 10.1128/JB.01163-07
Grosjean M, et al. Reassessment of the cooperativity between efflux system MexAB-OprM and cephalosporinase AmpC in the resistance of Pseudomonas aeruginosa to β-lactams. J Antimicrob Chemoth. 2021;76:536–9.
doi: 10.1093/jac/dkaa462
Masuda N, Gotoh N, Ohya S, Nishino T. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Ch. 1996;40:909–13.
doi: 10.1128/AAC.40.4.909
Purssell A, Poole K. Functional characterization of the NfxB repressor of the mexCD-oprJ multidrug efflux operon of Pseudomonas aeruginosa. Microbiology. 2013;159:2058–73.
pubmed: 23924707
doi: 10.1099/mic.0.069286-0
El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28:191–207.
pubmed: 25567227
pmcid: 4284305
doi: 10.1128/CMR.00058-14
Band VI, Weiss DS. Heteroresistance: A cause of unexplained antibiotic treatment failure? PLoS Pathog. 2019;15:e1007726.
pubmed: 31170271
pmcid: 6553791
doi: 10.1371/journal.ppat.1007726
Band VI, et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol. 2016;1:16053.
pubmed: 27572838
pmcid: 5154748
doi: 10.1038/nmicrobiol.2016.53
Nicoloff H, Hjort K, Levin BR, Andersson DI. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat Microbiol. 2019;4:504–14.
pubmed: 30742072
doi: 10.1038/s41564-018-0342-0
Hallander HO, Laurell G. Identification of cephalosporin-resistant Staphylococcus aureus with the disc diffusion method. Antimicrob Agents Chemother. 1972;1:422–6.
pubmed: 4670484
pmcid: 444236
doi: 10.1128/AAC.1.5.422
Hung KH, Wang MC, Huang AH, Yan JJ, Wu JJ. Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii. J Clin Microbiol. 2012;50:721–6.
pubmed: 22189112
pmcid: 3295183
doi: 10.1128/JCM.05085-11
Lu Y, et al. Quorum sensing regulates heteroresistance in Pseudomonas aeruginosa. Front Microbiol. 2022;13:1017707.
pubmed: 36386621
pmcid: 9650436
doi: 10.3389/fmicb.2022.1017707
Potrykus K, Cashel M. p)ppGpp: still magical?. Annu Rev Microbiol. 2008;62:35–51.
pubmed: 18454629
doi: 10.1146/annurev.micro.62.081307.162903
Kim H, Kim JH, Cho H, Ko KS. Overexpression of a DNA Methyltransferase increases persister cell formation in Acinetobacter baumannii. Microbiol Spectr. 2022;10:e0265522.
pubmed: 36416541
doi: 10.1128/spectrum.02655-22
Yu W, et al. Absence of tmRNA Increases the persistence to Cefotaxime and the Intercellular Accumulation of Metabolite GlcNAc in Aeromonas veronii. Front Cell Infect Microbiol. 2020;10:44.
pubmed: 32185140
pmcid: 7058587
doi: 10.3389/fcimb.2020.00044
Alkasir R, et al. Characterization and Transcriptome analysis of Acinetobacter baumannii persister cells. Micro Drug Resist. 2018;24:1466–74.
doi: 10.1089/mdr.2017.0341
Advancing Health through Innovation: New Drug Approvals 2019. United States Food and Drug Administration, Document: https://www.fda.gov/media/134493/download (2020).
Sato T, Yamawaki K. Cefiderocol: Discovery, chemistry, and in vivo profiles of a novel Siderophore Cephalosporin. Clin Infect Dis. 2019;69:S538–S543.
pubmed: 31724047
pmcid: 6853759
doi: 10.1093/cid/ciz826
Cook-Libin S, Sykes EME, Kornelsen V, Kumar A. Iron acquisition mechanisms and their role in the virulence of Acinetobacter baumannii. Infect Immun. 2022;90:e0022322.
Page MGP. The role of Iron and Siderophores in infection, and the development of Siderophore antibiotics. Clin Infect Dis. 2019;69:S529–S537.
pubmed: 31724044
pmcid: 6853763
doi: 10.1093/cid/ciz825
Ji C, Juarez-Hernandez RE, Miller MJ. Exploiting bacterial iron acquisition: siderophore conjugates. Future Med Chem. 2012;4:297–313.
pubmed: 22393938
doi: 10.4155/fmc.11.191
Ito A, et al. In Vitro antibacterial properties of cefiderocol, a Novel Siderophore Cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018;62:e01454-17.
Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics. 2022;11:723.
Malik S, Kaminski M, Landman D, Quale J. Cefiderocol resistance in Acinetobacter baumannii: Roles of beta-Lactamases, Siderophore receptors, and Penicillin binding Protein 3. Antimicrob Agents Chemother. 2020;64:e01221-20.
Poirel L, Sadek M, Nordmann P. Contribution of PER-Type and NDM-Type beta-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65:e0087721.
pubmed: 34252309
doi: 10.1128/AAC.00877-21
Klein S, et al. Rapid development of Cefiderocol resistance in Carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the Catecholate Siderophore receptor cirA. Clin Infect Dis. 2022;74:905–8.
pubmed: 34079986
doi: 10.1093/cid/ciab511
Lee N, Yuen KY, Kumana CR. Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Drugs. 2003;63:1511–24.
pubmed: 12834367
doi: 10.2165/00003495-200363140-00006
van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation beta-Lactam/beta-Lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–41.
pubmed: 27098166
pmcid: 4928383
doi: 10.1093/cid/ciw243
Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59:3509–17.
pubmed: 25845862
pmcid: 4432207
doi: 10.1128/AAC.00163-15
Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of Ceftolozane-Tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Ch. 2013;57:6305–10.
doi: 10.1128/AAC.01802-13
Flamm RK, Farrell DJ, Sader HS, Jones RN. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother. 2014;69:1589–98.
pubmed: 24562613
doi: 10.1093/jac/dku025
Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015;59:3656–9.
pubmed: 25845861
pmcid: 4432162
doi: 10.1128/AAC.05024-14
Farrag HA, Abdallah N, Shehata MMK, Awad EM. Natural outer membrane permeabilizers boost antibiotic action against irradiated-resistant bacteria. J Biomed Sci. 2019;26:69.
pubmed: 31500622
pmcid: 6732830
doi: 10.1186/s12929-019-0561-6
Chiu S, et al. Causes of polymyxin treatment failure and new derivatives to fill the gap. J Antibiot. 2022;75:593–609.
doi: 10.1038/s41429-022-00561-3
Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47:905–9.
pubmed: 12604520
pmcid: 149291
doi: 10.1128/AAC.47.3.905-909.2003
Pages JM, Peslier S, Keating TA, Lavigne JP, Nichols WW. Role of the outer membrane and Porins in susceptibility of beta-Lactamase-producing Enterobacteriaceae to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2015;60:1349–59.
pubmed: 26666933
doi: 10.1128/AAC.01585-15
Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Rescuing the last-line Polymyxins: Achievements and challenges. Pharm Rev. 2021;73:679–728.
pubmed: 33627412
pmcid: 7911091
doi: 10.1124/pharmrev.120.000020
Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother. 2017;72:1373–85.
pubmed: 28158732
doi: 10.1093/jac/dkw593
Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2019;74:953–60.
pubmed: 30590470
doi: 10.1093/jac/dky522
Morinaka A, et al. OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam ‘enhancer’. J Antimicrob Chemoth. 2015;70:2779–86.
doi: 10.1093/jac/dkv166
Kim S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49:D1388–D1395.
pubmed: 33151290
doi: 10.1093/nar/gkaa971